Artrya Limited (ASX:AYA) has emerged as one of the more closely watched names in the Australian health technology sector heading into the second half of 2026. The Perth-based company is developing and commercialising an artificial intelligence platform — branded Salix — designed to analyse coronary CT angiography (CCTA) scans and assist clinicians in detecting and managing coronary artery disease. With two FDA clearances secured for its flagship Salix modules and a growing roster of US hospital customers, AYA is at a pivotal stage in its commercial journey. The share price has reflected heightened interest, trading between a 52-week low of $0.56 and a high of $5.24, and an A$80 million capital raise completed in late 2025 has provided a pro forma cash position of around A$76.6 million as of April 2026. For investors interested in early-stage medical AI, Artrya is a story worth monitoring.

Why Artrya Is Attracting Investor Attention

The catalyst that has put AYA on investor watchlists is the convergence of FDA regulatory clearances and an emerging US reimbursement pathway. In August 2025, Artrya received 510(k) clearance from the US Food and Drug Administration for its Salix Coronary Plaque module — following earlier clearance of the Salix Coronary Anatomy module. Crucially, the Plaque module automatically qualifies for a Category I CPT reimbursement code, with US$950 per assessment taking effect from 1 January 2026. This combination of regulatory approval and a clear payment mechanism is precisely the kind of development that may attract sustained attention from healthcare-focused investors. Early commercial wins — including a five-year deal with Tanner Health and active integration with Northeast Georgia Health and Cone Health — signal the company is transitioning from development into early revenue generation.

Company Overview

Artrya Limited is a Perth-based medical technology company built around a mission to reduce the burden of coronary artery disease — the world's leading cause of death. Its flagship product, Salix, is a cloud-based AI software platform that automates the detection, characterisation, and reporting of coronary anatomy and plaque from CCTA scans, delivering results rapidly at the point of care. The platform is designed to augment cardiologist and radiologist workflows, enabling faster and more consistent assessments than traditional manual review. Artrya's primary commercial focus is the US market, where the scale of cardiac imaging — millions of CCTA scans performed annually — represents a substantial addressable opportunity. A third Salix module, Salix Coronary Flow, was being positioned for FDA submission as of mid-2026, representing the next potential regulatory catalyst.

Sector and Industry Position

Artrya operates at the intersection of two high-growth global themes: artificial intelligence in healthcare and cardiac diagnostics. The medical AI sector has attracted significant investment as health systems seek to reduce diagnostic backlogs, improve accuracy, and manage cost pressures. Within this space, cardiovascular AI is a particularly active area, with established device companies and startups competing for clinical adoption. Artrya's differentiation lies in its specific focus on CCTA-based coronary plaque analysis — a clinically meaningful capability for identifying high-risk plaque features often missed by conventional review. On the ASX, Artrya is a relatively rare example of a domestically developed medical software company with US FDA clearances and active US customer contracts, positioning it among a small cohort of Australian healthtech names that have successfully navigated US regulatory pathways.

Recent Market Interest

The share price of AYA has been notably volatile over the past year, consistent with a pre-profitability company executing against significant catalysts. The 52-week trading range of $0.56 to $5.24 reflects both the high-risk, high-optionality nature of the stock and the market's reaction to specific announcements — including the August 2025 FDA Plaque clearance and the September 2025 A$80 million capital raise. As of March 2026, the stock was observed trading around $2.85. The A$80 million raise attracted participation consistent with institutional engagement, and combined with the first multi-year US hospital deal announcement, contributed to periods of heightened trading interest. The involvement of major US health systems in the SAPPHIRE study has also kept AYA in the market conversation.

Key Growth Themes

US FDA Clearances and CPT Reimbursement

The twin FDA clearances for Salix Coronary Anatomy and Salix Coronary Plaque are the foundational building blocks of Artrya's US commercial strategy. The Category I CPT reimbursement code — providing US$950 per automated plaque analysis from 1 January 2026 — is a material development because it removes a significant adoption barrier: when a health system can generate revenue from deploying Salix, the commercial conversation shifts from cost-centre to revenue-positive. The pipeline extends further with the Salix Coronary Flow module targeting FDA submission, and a successful Q-Submission meeting with the FDA reportedly providing clear guidance on the 510(k) pathway for that module.

Growing US Hospital Network and the SAPPHIRE Study

Artrya's US strategy centres on a growing network of hospital partnerships. Commercial agreements with Tanner Health, Northeast Georgia Health, and Cone Health provide early revenue anchor points. Beyond these, the SAPPHIRE study — a multi-centre, real-world study evaluating the prognostic utility of Salix Plaque Analysis — is attracting notable institutional partners including Ascension Healthcare, Mass General Brigham, Huntsville Hospital Heart Centre, HCA Midwest Health, and Piedmont Healthcare. These relationships build clinical evidence and pipeline for future commercial conversions: collectively, participating institutions reportedly conduct approximately 400,000 CCTA scans annually, representing a substantial potential addressable volume for Salix.

Australian Revenue Base and Sonic Healthcare

While the US is the primary focus, Artrya also has a developing domestic revenue stream through its three-year agreement with Sonic Healthcare, which commenced generating revenue in the fourth quarter of 2025. Salix Coronary Anatomy is being progressively rolled out across approximately 30 Sonic cardiac imaging centres, with the contribution potentially ramping toward around A$500,000 annually by FY26. While modest against the US opportunity, the Sonic agreement provides a domestic reference point and contributes to the company's early revenue profile.

Risks Investors Should Understand

Artrya is an early-stage, pre-mature revenue company in a capital-intensive sector, and investors should approach it with a clear understanding of the risks involved. The company reported a net loss of approximately A$10.74 million in its most recent half-year period, reflecting the costs associated with commercialisation, clinical studies, and technology development. While the A$76.6 million pro forma cash position as of April 2026 provides substantial runway, continued losses will erode this over time, and the timeline to breakeven remains uncertain.

  • Revenue is at an early stage: customer receipts remain very modest relative to operating costs, and the path to profitability depends heavily on successful US adoption at scale.
  • Regulatory risk: the Salix Coronary Flow module still requires FDA clearance, and any delays or setbacks in that process could affect growth timelines.
  • Competition: the medical AI imaging space is attracting well-resourced incumbents and startups globally, and Artrya faces ongoing competitive pressure.
  • Clinical adoption: even with FDA clearance and CPT reimbursement, hospital systems can be slow to adopt new diagnostic technologies, and sales cycles may be longer than anticipated.
  • Share price volatility: the stock has demonstrated a wide trading range, and significant price swings in response to announcements — positive or negative — remain a characteristic of this investment.

What Investors May Watch Next

The FDA submission and potential clearance of the Salix Coronary Flow module is the single most important near-term milestone for AYA, as it would complete the core Salix module suite and open additional reimbursement opportunities. Management had been targeting an end-of-June 2026 filing, making it an event investors may watch closely. Progress on commercial conversions from SAPPHIRE participants — particularly Ascension Healthcare and Mass General Brigham — could represent a meaningful step-up in US revenue. Quarterly cash flow updates will also be monitored by investors tracking burn rate against the A$76.6 million cash position, while any new commercial signings or integration progress at existing hospital customers may attract renewed interest in AYA.

Long-Term Outlook

The long-term case for Artrya rests on the thesis that AI-driven cardiac imaging analysis will become standard in CCTA workflows globally, and that Salix is well-positioned to be a leading platform in that transition. The scale of the cardiovascular disease burden — and the diagnostic imaging it generates — means even modest penetration of the addressable market could underpin a meaningful revenue base. Whether Artrya realises this potential depends on FDA regulatory success, converting study participants to commercial customers, cash discipline, and competitive positioning as the medical AI landscape evolves. For investors with a longer horizon and appetite for higher-risk, high-optionality healthcare technology, AYA remains one of the more closely watched Australian medical AI stories of 2026.